Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk and Eli Lilly have filed a motion to dismiss in the MDL over Ozempic and similar drugs. The defendants are asking the court to throw out 12 of the plaintiffs' 17 claims. The ...

The Eli Lilly submission has not been made public, but people briefed on its contents confirmed the inclusion. A PBS listing means the government subsidises most of the cost of a drug. Ozempic is ...

Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled to 19.87 billion Danish kroner. According to Reuters, investors and analysts expect Eli Lilly to ...

Eli Lilly’s profit doubled in the fourth quarter ... weight people lose while taking the injections. They compete with Ozempic and Wegovy from the Danish drugmaker Novo Nordisk, which also ...